Disease: Stage IV Gastric Carcinoma, Stage IV Nasopharyngeal Carcinoma, T-Cell Lymphoma Stage IV, Stage IV Adult Hodgkin Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma

Disease info:

Nasopharyngeal (nay-zoh-fuh-RIN-jee-ul) carcinoma is cancer that occurs in the nasopharynx, which is located behind your nose and above the back of your throat.

Gastric (stomach) cancer occurs when cancer cells form in the lining of the stomach. Risk factors include smoking, infection with H. pylori bacteria, and certain inherited conditions.

Nasopharyngeal carcinoma is difficult to detect early. That's probably because the nasopharynx isn't easy to examine and symptoms of nasopharyngeal carcinoma mimic those of other, more-common conditions

Frequency:
Approximately 0.9 percent of men and women will be diagnosed with stomach cancer at some point during their lifetime, based on 2014-2016 data. Nasopharyngeal cancer is quite rare with less than one case for every 100,000 people.
Official title:
A Phase I/II Trial of PD-1 Knockout EBV-CTLs for Advanced Stage EBV Associated Malignancies
Who:

Principal Investigator: Baorui Liu, MD  The Comprehensive Cancer Centre of Drum Tower Hospital,

Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University

Sponsor:

Yang Yang, MD, PhD, MSCR, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Partners:
Locations:

China, Jiangsu

Study start:
Apr. 7, 2017
Enrollment:
20 participants
Gene editing method:
CRISPR-Cas9
Gene:
Programmed cell death protein 1 (PD-1)
Vector:
No information
IndicatorIndicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting

Description

This study will evaluate the safety of PD-1 knockout EBV-CTL (Epstein Barr Virus-Specific Cytotoxic T Lymphocytes) cells in treating EBV (Epstein-Barr virus) positive advanced stage malignancies. Blood samples will also be collected for research purposes.

This is a study of CRISPR-Cas9 mediated PD-1 knockout-T cells from autologous origin. Patients are assigned to receive 4 circles of cell therapy. The safety and clinical response are evaluated. Biomarkers and immunological markers are also monitored.